Drug Trial Radar · NCT06703606
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
May 13, 2025
Primary completion
May 5, 2027
Study completion May 5, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to learn about safety, how the body processes marstacimab and how it works in patients with severe hemophilia A without inhibitors. Hemophilia A is rare bleeding disorder where the blood doesn't clot normally. This causes a person to bleed a lot, even from a small cut. These patients who are on emicizumab medicine for routine prophylaxis for at least 6 months, and desire to switch to marstacimab medicine. Inhibitors are antibodies that the immune system develops because it sees the infused clotting factor as a foreign substance that needs to be destroyed. Antibodies are proteins that eat up the activated factor before it has time to stop the bleeding. Prophylaxis are preventive medicines. This study is seeking for participants: * with severe Hemophilia A withouth inhibitors who are on emicizumab treatment for at least 6 months. * must be 12 to less than 75 years old * must have a body weight of at least 35 kilograms. The results from this study will serve as a guide to doctors and their hemophilia A patients who will change their medicines in the real-world clinical setting. Patients who can take part in the study will receive marstacimab medicine as weekly injections under the skin of 150 milligrams for 4 months. Study treatment with marstacimab will be initiated no earlier than 14 days after last dose of emicizumab. The study can last up to 6 months. The sponsor will provide marstacimab. Patients will continue their usual treatment with the infused clotting factor for their bleeds when taking part in the study. Roll-over into an optional study treatment extension period will be available to participants who wish to continue prophylaxis with marstacimab in countries where it is not commercially available.
Conditions
- Severe Hemophilia A
Interventions
MARSTACIMABDrug
Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of marstacimab-related adverse events (AEs)Time frame: Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment
- Incidence of marstacimab-related serious AEs (SAEs)Time frame: Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Altman Clinical and Translational Research Institute-IDS
La Jolla, California · Recruiting
Altman Clinical and Translational Research Institute
La Jolla, California · Recruiting
Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center
Los Angeles, California · Recruiting
UCSD Center for Bleeding and Clotting Disorders
San Diego, California · Recruiting
Brody School of Medicine at East Carolina University
Greenville, North Carolina · Recruiting
ECU Health Medical Center
Greenville, North Carolina · Recruiting
Nirmal Hospital Pvt Ltd.
Surat, Gujarat, India · Recruiting
K J Somaiya Hospital & Research Centre
Mumbai, Maharashtra, India · Recruiting
Istanbul Universitesi Tıp Fakultesi Onkoloji Enstitusu
Fatih, İ̇stanbul, Turkey (Türkiye) · Recruiting
Ege University Faculty of Medicine Dean's Office
Bornova, İzmir, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.